Skip to main content

ENTX

Stock
Health Care
Biotechnology

Performance overview

ENTX Price
Price Chart

Forward-looking statistics

Beta
0.51
Risk
79.03%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

entera bio ltd. is a biotechnology company located in israel.

Company info

SectorHealth Care
IndustryBiotechnology
Employees17
Market cap$71.6M

Fundamentals

Enterprise value
Revenue
Revenue per employee
Profit margin
Debt to equity

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)
Dividend per share
Revenue per share
Avg trading volume (30 day)
Avg trading volume (10 day)
Put-call ratio

Macro factor sensitivity

Growth+2.1
Credit+4.6
Liquidity-1.6
Inflation+1.8
Commodities-0.3
Interest Rates-2.5

Valuation

Dividend yield0.00%
PEG Ratio
Price to sales
P/E Ratio-3.69
Enterprise Value to Revenue
Price to book

Upcoming events

Next earnings dayMay 10, 2025
Next dividend day
Ex. dividend day

News

Entera Bio Ltd. (ENTX) Reports Q3 Loss, Tops Revenue Estimates

Entera Bio Ltd. (ENTX) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.05.

Zacks Investment Research (November 8, 2024)
Entera Bio Outlines Pivotal Osteoporosis Trial, Names New CEO

Following its End of Phase 2 Meeting with the FDA, Entera Bio Ltd (NASDAQ: ENTX) has designed the pivotal study for EB613 as an 18-month double-blind placebo-controlled study, followed by a 6-month open-label transition to alendronate for all patients. The study's primary.

Benzinga (July 18, 2022)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free